Entry

D07299                      Drug

Name

Lacosamide (JAN/USAN/INN);
Erlosamide;
Vimpat (TN)

Product

VIMPAT (Lohxa), VIMPAT (UCB), LACOSAMIDE (VistaPharm)

Generic

LACOSAMIDE (Alembic Pharmaceuticals), LACOSAMIDE (American Health Packaging), LACOSAMIDE (Amneal Pharmaceuticals LLC), LACOSAMIDE (Ascend Laboratories), LACOSAMIDE (AvKARE), LACOSAMIDE (Breckenridge Pharmaceutical), LACOSAMIDE (Camber Pharmaceuticals), LACOSAMIDE (Camber Pharmaceuticals), LACOSAMIDE (Fresenius Kabi USA), LACOSAMIDE (Glenmark Pharmaceuticals Inc. USA), LACOSAMIDE (Indoco Remedies Limited), LACOSAMIDE (Indoco Remedies Limited), LACOSAMIDE (MSN LABORATORIES PRIVATE LIMITED), LACOSAMIDE (Major Pharmaceuticals), LACOSAMIDE (NorthStar RxLLC), LACOSAMIDE (Novitium Pharma LLC), LACOSAMIDE (Sagent Pharmaceuticals), LACOSAMIDE (ScieGen Pharmaceuticals), LACOSAMIDE (Sun Pharmaceutical Industries), LACOSAMIDE (Tris Pharma), LACOSAMIDE (Zydus Lifesciences Limited), LACOSAMIDE (Zydus Pharmaceuticals USA), LACOSAMIDE ORAL SOLUTION (Ascend Laboratories)

Formula

C13H18N2O3

Exact mass

250.1317

Mol weight

250.2936

Structure

Class

Neuropsychiatric agent
DG03199  Antiepileptic agent
Metabolizing enzyme substrate
DG01642  CYP2C9 substrate
DG01639  CYP2C19 substrate
DG01633  CYP3A/CYP3A4 substrate
  DG02913  CYP3A4 substrate
Metabolizing enzyme inhibitor
DG01933  CYP2C19 inhibitor

Remark

Therapeutic category:

1139

ATC code:

N03AX18

Product:

D07299<JP/US>

Efficacy

Antiepileptic, Pain relief (neuropathic)

Comment

Treatment of epilepsy and neuropathic pain

Target

SCN3A [HSA:6328] [KO:K04836]
SCN9A [HSA:6335] [KO:K04841]
SCN10A [HSA:6336] [KO:K04842]

Metabolism

Enzyme: CYP3A4 [HSA:1576], CYP2C9 [HSA:1559], CYP2C19 [HSA:1557]

Interaction

CYP inhibition: CYP2C19 [HSA:1557]

Brite

Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
  N03 ANTIEPILEPTICS
   N03A ANTIEPILEPTICS
    N03AX Other antiepileptics
     N03AX18 Lacosamide
      D07299  Lacosamide (JAN/USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Anticonvulsants
  Sodium Channel Agents
   Lacosamide
    D07299  Lacosamide (JAN/USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
1  Agents affecting nervous system and sensory organs
  11  Agents affecting central nervous system
   113  Antiepileptics
    1139  Others
     D07299  Lacosamide (JAN/USAN/INN)
Drug groups [BR:br08330]
Neuropsychiatric agent
  DG03199  Antiepileptic agent
   D07299  Lacosamide
Metabolizing enzyme substrate
  DG01642  CYP2C9 substrate
   D07299  Lacosamide
  DG01639  CYP2C19 substrate
   D07299  Lacosamide
  DG01633  CYP3A/CYP3A4 substrate
   DG02913  CYP3A4 substrate
    D07299  Lacosamide
Metabolizing enzyme inhibitor
  DG01933  CYP2C19 inhibitor
   D07299  Lacosamide
Target-based classification of drugs [BR:br08310]
Ion channels
  Voltage-gated ion channels
   Sodium channels
    SCN3A
     D07299  Lacosamide (JAN/USAN/INN) <JP/US>
    SCN9A
     D07299  Lacosamide (JAN/USAN/INN) <JP/US>
    SCN10A
     D07299  Lacosamide (JAN/USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
  D07299
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
  D07299
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
  D07299
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
  D07299
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
  D07299
Pharmacogenomic biomarkers [br08341.html]
Polymorphisms and mutations affecting drug response
  D07299

Other DBs

CAS:	175481-36-4

PubChem:

51091636

LigandBox:

D07299

KCF data

ATOM        18
            1   C8y C    21.1332  -17.9117
            2   C1b C    22.3451  -17.2121
            3   N1b N    23.5571  -17.9117
            4   C5a C    24.7689  -17.2121
            5   C1c C    25.9808  -17.9117
            6   C1b C    27.1927  -17.2121
            7   O2a O    28.4046  -17.9117
            8   C8x C    19.9214  -17.2121
            9   C8x C    18.7094  -17.9117
            10  C8x C    18.7094  -19.3111
            11  C8x C    19.9214  -20.0108
            12  C8x C    21.1332  -19.3111
            13  O5a O    24.7689  -15.8127
            14  N1b N    25.9808  -19.3110
            15  C1a C    29.6205  -17.2098
            16  C5a C    24.7564  -20.0179
            17  C1a C    23.5627  -19.3285
            18  O5a O    24.7562  -21.4198
BOND        18
            1     1   2 1
            2     2   3 1
            3     3   4 1
            4     4   5 1
            5     5   6 1
            6     6   7 1
            7     1   8 2
            8     8   9 1
            9     9  10 2
            10   10  11 1
            11   11  12 2
            12    1  12 1
            13    4  13 2
            14    5  14 1 #Up
            15    7  15 1
            16   14  16 1
            17   16  17 1
            18   16  18 2